ECS

ECS Awarded $190M AI/ML Contract from DEVCOM Army Research Lab

Retrieved on: 
Tuesday, March 5, 2024

ECS, a leader in advanced technology, science, and engineering solutions and an ASGN (NYSE: ASGN) brand, received a three-year, $190 million contract from the United States Army Combat Capabilities Development Command (DEVCOM) Army Research Lab (ARL).

Key Points: 
  • ECS, a leader in advanced technology, science, and engineering solutions and an ASGN (NYSE: ASGN) brand, received a three-year, $190 million contract from the United States Army Combat Capabilities Development Command (DEVCOM) Army Research Lab (ARL).
  • As prime contractor, ECS will serve as a system integrator for DEVCOM ARL, delivering and integrating artificial intelligence (AI) capabilities for Department of Defense (DoD) services and combatant commands.
  • The contract, awarded in Q3 of 2023, is a new initiative helping aid DoD objectives through the expansion and extension of key AI research.
  • “ECS has a long history of providing mission solutions to the DoD including cloud, cyber, data, and AI solutions,” said Marshall Thames , senior vice president of mission solutions at ECS.

Igentify Launches New NIPT and Pharmacogenomics Offerings

Retrieved on: 
Tuesday, March 5, 2024

Igentify , a digital health company alleviating bottlenecks in the genetic testing process, announced the launch of its Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings via the Digital Genetic Assistant platform.

Key Points: 
  • Igentify , a digital health company alleviating bottlenecks in the genetic testing process, announced the launch of its Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings via the Digital Genetic Assistant platform.
  • This new roll-out comes in addition to their Expanded Carrier Screening (ECS) offering.
  • The NIPT workflow includes a patient web-app that facilitates all aspects of patient intake, including an ACOG-compliant consenting process using Igentify’s proprietary video technology to create highly personalized educational videos for each patient.
  • “We are thrilled to expand the accessibility of our platform with programs focused on non-invasive prenatal testing and pharmacogenomics,” said Elliott Greenspan, Chief Innovation Officer and Co-founder of Igentify.

ECS President John Heneghan Named Wash100 Award Winner

Retrieved on: 
Wednesday, February 21, 2024

ECS , a leader in advanced technology, science, and engineering solutions and an ASGN (NYSE: ASGN) brand, announced today that President John Heneghan has been recognized as a 2024 Wash100 Award winner by Executive Mosaic, an international leadership organization and media company.

Key Points: 
  • ECS , a leader in advanced technology, science, and engineering solutions and an ASGN (NYSE: ASGN) brand, announced today that President John Heneghan has been recognized as a 2024 Wash100 Award winner by Executive Mosaic, an international leadership organization and media company.
  • This marks the third consecutive year that Heneghan has been recognized on the list.
  • Heneghan assumed the role of ECS president in 2022.
  • “I’m proud to be named to the Wash100 list once again, because it reflects the value of the work we do and the impact our teams make on government missions,” said Heneghan.

Episcopal Relief & Development Partners With Episcopal Community Services in Response to Flooding in San Diego

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 7, 2024 /PRNewswire-PRWeb/ -- Episcopal Relief & Development is partnering with Episcopal Community Services (ECS) in San Diego, California to provide emergency relief and recovery support to nine families affected by the heavy rains and damaging flooding in January.

Key Points: 
  • Partnering with Episcopal Community Services (ECS) to support families affected by heavy rains and damaging flooding.
  • NEW YORK, March 7, 2024 /PRNewswire-PRWeb/ -- Episcopal Relief & Development is partnering with Episcopal Community Services (ECS) in San Diego, California to provide emergency relief and recovery support to nine families affected by the heavy rains and damaging flooding in January.
  • The water overwhelmed the city's stormwater system, and emergency services needed to rescue hundreds of people from their homes in low-lying areas.
  • As communities nationwide confront the escalating challenges of climate-induced flooding, exacerbated by infrastructure vulnerabilities, Episcopal Relief & Development is at the forefront of providing support.

Unisys Announces 4Q and Full-Year 2023 Results

Retrieved on: 
Wednesday, February 21, 2024

BLUE BELL, Pa., Feb. 21, 2024 /PRNewswire/ -- Unisys (NYSE: UIS) reported financial results for the fourth quarter and full year 2023.

Key Points: 
  • Backlog was $3.01 billion for the fourth quarter 2023 compared to $2.92 billion for the fourth quarter of 2022 and $2.38 billion in the third quarter of 2023.
  • Unisys will hold a conference call with the financial community on Wednesday, February 21 at 8 a.m. Eastern Time to discuss the results and 2024 financial guidance.
  • The live, listen-only webcast, as well as the accompanying presentation materials, can be accessed on the Unisys Investor Website at www.unisys.com/investor .
  • In addition, domestic callers can dial 1-844-695-5518 and international callers can dial 1-412-902-6749 and provide the following conference passcode: Unisys Corporation Call.

SurgePays Taps Derron Winfrey as Vice President

Retrieved on: 
Friday, February 16, 2024

BARTLETT, Tenn., Feb. 16, 2024 (GLOBE NEWSWIRE) -- SurgePays, Inc. (Nasdaq: SURG) (“SurgePays” or the “Company”), a technology and telecommunications company focused on the underbanked and underserved communities, announced today the appointment of Fintech and prepaid industry veteran Derron Winfrey as vice president, business development of the Company.

Key Points: 
  • BARTLETT, Tenn., Feb. 16, 2024 (GLOBE NEWSWIRE) -- SurgePays, Inc. (Nasdaq: SURG) (“SurgePays” or the “Company”), a technology and telecommunications company focused on the underbanked and underserved communities, announced today the appointment of Fintech and prepaid industry veteran Derron Winfrey as vice president, business development of the Company.
  • Upon joining SurgePays, he became president of SurgePays' prepaid division and has been serving in various business development and advisory roles.
  • In his new position, Mr. Winfrey will work with SurgePays President Jeremy Gies to help drive innovation by discovering, developing, and implementing new fintech products and services.
  • "Derron helped build the foundation of SurgePays' prepaid business," said Jeremy Gies, president of SurgePays.

Sila Services Continues Central Pennsylvania Expansion with Acquisition of ECS Comfort Heating & Cooling

Retrieved on: 
Thursday, February 15, 2024

Key Points: 
  • PHILADELPHIA, Feb. 15, 2024 /PRNewswire/ -- Sila Services, LLC announced its continued expansion into Central Pennsylvania with the recent acquisition of ECS Comfort Heating & Cooling.
  • Based in Palmyra, PA, ECS Comfort specializes in both residential and light commercial heating, cooling, and water heating system service and installations across Lebanon, Dauphin, and Lancaster counties.
  • "We are pleased to take this significant step in further expanding our footprint in the Central Pennsylvania region with the acquisition of ECS Comfort Heating & Cooling," stated Jason Rabbino, CEO of Sila Services.
  • We look forward to working with Andy Sattazahn and his tremendous team in building on the strong foundation ECS Comfort has established over the past 35 years and delivering innovative, unparalleled comfort solutions to our growing customer base across the Central Pennsylvania region."

Kiosk Industry News February 2024

Retrieved on: 
Monday, February 12, 2024

WESTMINSTER, Colo., Feb. 12, 2024 /PRNewswire/ -- The Kiosk Association's mission is to inform and educate on self-service.

Key Points: 
  • WESTMINSTER, Colo., Feb. 12, 2024 /PRNewswire/ -- The Kiosk Association's mission is to inform and educate on self-service.
  • If you follow accessibility guidelines and encourage ADA and would like to be recognized, contact us at [email protected]
    This month it is healthcare and HIMSS 2024.
  • We'll have 7 demos including Storm Interface, ImageHOLDERs, Vispero JAWS, Dolphin Screen Reader, Entropy (ECS) kiosk, Olea Kiosks, Kiosk Innovations + latest telehealth by RedyRef.
  • You may want to allocate budget for retrofits…
    Featured: Elevating restaurant finances - in-depth ROI review of three different restaurant kiosk deployments and their return on investment numbers (and dollars) including cost savings, employee costs and income.

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Retrieved on: 
Thursday, February 8, 2024

COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.

Key Points: 
  • The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology.
  • COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.
  • Through rigorous research and development efforts, Tetra Pharm Technologies has unlocked the potential of this biological system to address one of the most pressing health challenges of our time – excessive appetite and weight gain.
  • By specifically targeting the endocannabinoid system, Tetra Pharm Technologies' solution holds promise for combating obesity and related metabolic disorders, with far-reaching implications for public health.

Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing

Retrieved on: 
Thursday, February 8, 2024

COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.

Key Points: 
  • The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology.
  • COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.
  • Through rigorous research and development efforts, Tetra Pharm Technologies has unlocked the potential of this biological system to address one of the most pressing health challenges of our time – excessive appetite and weight gain.
  • By specifically targeting the endocannabinoid system, Tetra Pharm Technologies' solution holds promise for combating obesity and related metabolic disorders, with far-reaching implications for public health.